Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PF3G | ISIN: US21900C3088 | Ticker-Symbol: 19KA
Tradegate
18.09.25 | 17:33
9,700 Euro
+2,65 % +0,250
1-Jahres-Chart
CORMEDIX INC Chart 1 Jahr
5-Tage-Chart
CORMEDIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,65010,00020:40
9,65010,00020:40

Aktuelle News zur CORMEDIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:10Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?2
CORMEDIX Aktie jetzt für 0€ handeln
MoCorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?5
FrMajor Exercise Alert: Beth Zelnick Kaufman Exercises Options Worth $495K At Cormedix1
FrStrategic Sale: Elizabeth Hurlburt Decides To Exercise Options Worth $635K At Cormedix5
09.09.Analyst Expectations For Cormedix's Future5
09.09.CorMedix-Investment in Talphera schafft Pipeline-Optionalität - JMP bestätigt Rating8
09.09.CorMedix stock investment in Talphera adds pipeline optionality, JMP reiterates1
09.09.Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors3
08.09.Talphera Secures Up To $29 Mln In Private Placement Led By CorMedix2
08.09.CorMedix, Inc.: CorMedix Announces Strategic Minority Investment in Talphera211BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
► Artikel lesen
02.09.Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?6
02.09.CorMedix Inc. - 8-K, Current Report-
02.09.CorMedix, Inc.: CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team204- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue...
► Artikel lesen
08.08.CorMedix signs agreement to acquire Melinta for $300m7
07.08.CorMedix expands infectious disease portfolio with $300M acquisition of Melinta3
07.08.CorMedix To Acquire Melinta Therapeutics In $300 Mln Deal To Expand Infectious Disease Portfolio11
07.08.CorMedix Inc. - 10-Q, Quarterly Report2
07.08.CorMedix GAAP EPS of $0.28 beats by $0.09, revenue of $39.74M beats by $3.82M9
07.08.CorMedix Inc. - 8-K, Current Report1
07.08.CorMedix to acquire Melinta Therapeutics in $300 million deal5
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1